MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to predict severe outcomes up to 72 hours and mortality 14 days in advance in patients with acute ...

Newark, NJ, Sept. 10, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global capillary and venous blood sampling market is expected to grow from USD 1.5 billion in 2019 and ...

BOSTON, July 31, 2024 /PRNewswire/ -- O'Ryan.Health, a leader in at-home pediatric healthcare innovation, today announced it has become the first US company to launch two, parent-led observational ...

As COVID-19 seems to be making a comeback in many areas of the world, including Japan, a new study published on the preprint server medRxiv* in October 2020 shows the relevance of microsamples of ...

A new needle-free blood test, TAP, launched by UHMBT NHS Trust, transforms care for patients with learning disabilities or needle phobia ...